Retatrutide is an investigational multi-receptor agonist peptide that has gained attention for its unique mechanism targeting three key metabolic hormone receptors: GLP-1, GIP, and glucagon receptors. It represents the next evolution in incretin-based peptide research, building upon the success of Semaglutide and Tirzepatide.

Developed by Eli Lilly, Retatrutide is currently under clinical investigation for its potential to drastically enhance fat loss, glucose regulation, and metabolic health. Early-stage studies suggest that it outperforms existing GLP-1 agonists in both magnitude and speed of weight loss, making it a highly promising candidate for metabolic research.

This product is strictly intended for research purposes only and is not for human consumption. It comes in a lyophilized powder form suitable for sterile reconstitution and controlled laboratory experimentation.

Mechanism of Action:

Retatrutide is a triple agonist targeting:

• GLP-1 (Glucagon-like peptide-1) receptor

• GIP (Gastric inhibitory polypeptide) receptor

• Glucagon receptor

These receptors work synergistically to regulate blood sugar, appetite, and energy expenditure. By activating all three simultaneously, Retatrutide creates a potent metabolic response that could drive significant changes in fat metabolism, glucose control, and satiety signals in preclinical and early clinical models.

• GLP-1 receptor activation reduces appetite, delays gastric emptying, and improves insulin secretion.

• GIP receptor activation enhances insulin release in response to glucose and supports lipid metabolism.

• Glucagon receptor activation promotes energy expenditure and fat oxidation, increasing basal metabolic rate.

Theoretical Benefits of Retatrutide:

All benefits are based on emerging clinical trial data and preclinical findings. Retatrutide is sold for research use only.

1. Extreme Fat Loss Potential:

In early Phase 1 trials, participants on Retatrutide lost over 24% of body weight in under a year. This far exceeds the average 10–15% seen with Semaglutide or Tirzepatide. For researchers, Retatrutide offers a unique opportunity to study aggressive fat loss mechanisms through multi-receptor stimulation.

2. Superior Appetite Suppression:

GLP-1 and GIP agonism, coupled with glucagon receptor stimulation, leads to profound appetite suppression. Rodent models showed a significant reduction in food-seeking behavior, and clinical data suggest similar patterns in humans.

3. Enhanced Basal Metabolic Rate (BMR):

Glucagon receptor activation increases thermogenesis and fat oxidation. This could make Retatrutide a valuable tool in metabolic disorder research beyond weight loss — including studies on hypothyroidism, PCOS, and metabolic syndrome.

4. Glucose Control:

Like Semaglutide and Tirzepatide, Retatrutide improves insulin sensitivity and glucose disposal rates. It suppresses glucagon overproduction in a glucose-dependent manner, stabilizing blood sugar and reducing insulin resistance.

5. Cardiovascular Protection (Theoretical):

Incretin-based therapies often show beneficial effects on lipid profiles, blood pressure, and inflammation markers. Retatrutide’s triple agonism may lead to even more pronounced cardiovascular protection, though this remains an area of ongoing investigation.

6. Neuroprotective Effects:

GLP-1 receptor agonists have been studied for their potential role in slowing neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Retatrutide could open new doors for peptide research in neurobiology.

Clinical Data & Studies:

• Eli Lilly Phase 1 & 2 Trials: In published trial data (NCT04881760), participants treated with the highest dose of Retatrutide lost 24.2% of their body weight over 48 weeks. This set a new benchmark for investigational weight-loss compounds.

• Lilly Obesity Pipeline Research (2023): Retatrutide outperformed both Semaglutide and Tirzepatide in terms of speed and scale of weight loss. Participants tolerated it well, with gastrointestinal effects being the most common side effect.

• Animal Studies: Mice administered Retatrutide showed superior fat reduction and increased locomotion compared to monotherapy GLP-1 agonists. There was also notable reduction in hepatic fat storage and improved liver enzyme markers.

Suggested Research Use:

• Dose for Rodent Studies: 0.1–0.3mg/kg daily

• Typical Study Duration: 6–12 weeks

• Reconstitution: Reconstitute 20mg vial with 2–4mL bacteriostatic water to yield 5–10mg/mL solution

• Storage: Keep lyophilized powder refrigerated at 2–8°C; once reconstituted, store for up to 30 days under sterile conditions

Reported Side Effects in Research

• Nausea

• Reduced appetite

• Mild diarrhea or constipation

• Headaches (less common)

• Fatigue (early stages)

These were dose-dependent and typically subsided within 1–2 weeks. Retatrutide has a safety profile comparable to other incretin therapies in most preclinical settings.

Legal & Safety Notice:

Retatrutide is not approved for therapeutic or medical use. It is provided exclusively for in vitro and in vivo laboratory research. It is not to be administered to humans or animals, and any off-label or unauthorized use is strictly prohibited. All buyers are responsible for compliance with their local laws and research regulations.